Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 10/2006

01-10-2006 | Research Articles

Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy

Authors: Manuel Cobo Dols, Esther Villar Chamorro, Inmaculada Alés Díaz, Silvia Gil Calle, Julia Alcalde García, Vanesa Gutiérrez Calderón, Francisco Carabantes Ocón, Álvaro Montesa Pino, Juan J. Bretón García, Manuel Benavides Orgaz

Published in: Clinical and Translational Oncology | Issue 10/2006

Login to get access
Metadata
Title
Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy
Authors
Manuel Cobo Dols
Esther Villar Chamorro
Inmaculada Alés Díaz
Silvia Gil Calle
Julia Alcalde García
Vanesa Gutiérrez Calderón
Francisco Carabantes Ocón
Álvaro Montesa Pino
Juan J. Bretón García
Manuel Benavides Orgaz
Publication date
01-10-2006
Publisher
Springer-Verlag
Published in
Clinical and Translational Oncology / Issue 10/2006
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-006-0121-x

Other articles of this Issue 10/2006

Clinical and Translational Oncology 10/2006 Go to the issue

Brief Research Articles

Feasibilty study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function

Correspondence

Spanish co-operative group of medical neuro-oncology (Genom)

Research Articles

Protocol for the implantation of a venous access device (Port-A-Cath System). The complications and solutions found in 560 cases

Editorial

Advances in neuroblastoma research

Educational Series

Anticancer drug discovery and pharmaceutical chemistry: a history

Educational Series

Molecular biology of renal cell carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits